Cargando…

Postprandial decrease in LDL-cholesterol in men with metabolic syndrome

BACKGROUND: In some epidemiological studies, blood lipids are determined at non-fasting state, which may impact cardiovascular risk estimation. The aim of this study was to evaluate postprandial LDL-C changes in men with newly diagnosed metabolic syndrome (MetSy). METHODS: 36 male patients were exam...

Descripción completa

Detalles Bibliográficos
Autores principales: Skoczyńska, Anna, Turczyn, Barbara, Wojakowska, Anna, Kreczyńska, Bogusława, Skoczyńska, Marta, Wojtas, Kamila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter Open 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153088/
https://www.ncbi.nlm.nih.gov/pubmed/28352689
http://dx.doi.org/10.1515/med-2015-0025
Descripción
Sumario:BACKGROUND: In some epidemiological studies, blood lipids are determined at non-fasting state, which may impact cardiovascular risk estimation. The aim of this study was to evaluate postprandial LDL-C changes in men with newly diagnosed metabolic syndrome (MetSy). METHODS: 36 male patients were examined: 12 men with and 24 men without MetSy. The fat tolerance test was performed before and after a three-month hypolipidemic treatment. Serum lipids were measured using routine methods, lipid peroxides (LPO) colorimetrically, apolipoproteins A-I, B, and hsCRP immunoturbidimetrically. RESULTS: The postprandial increase in triglycerides was associated with a decrease in LDL-C and a small decrease in apo B. In men with MetSy, the mean change in LDL-C (−19.5 ± 2.3 mg/dl) was greater than in healthy men (−5.7 ± 3.8 mg/dl). All lipid changes (ΔTG, ΔLDL-C and ΔLPO) were linearly dependent on the postprandial non-LDL-cholesterol. After three months of hypolipidemic treatment, in all men with MetSy, the apoB/apoA-I ratio remained the same as before the therapy. CONCLUSION: In men diagnosed with MetSy, postprandial decreases in LDL-cholesterol may cause underestimation of cardiovascular risk. After three months of hypolipidemic treatment, there was only a partial reduction in this risk, as the apoB/apoA-I ratio remained the same.